Key result
Screening ~9,900 compounds reveals CP-724714 reduces CRISPR off-target effects while Clofarabine accelerates editing.
Why the study?
A major limitation of CRISPR/Cas9 in gene therapy is biosafety issues caused by off-target effects, creating a need for compounds that modulate genome editing efficiency to improve safety and effectiveness.
High-throughput screening identified novel compounds that can modulate CRISPR/Cas9 genome editing efficiency and off-target effects, providing potential tools for optimizing genetic manipulation.
These modulators are hypothesis-generating for CRISPR optimization; leaves open translation to cardiovascular gene-editing applications.
Genome editing is a promising therapeutic strategy for genetic disorders by modifying the genome precisely, especially the CRISPR/Cas9 system. However, a major limitation of CRISPR/Cas9 in gene therapy is the biosafety issues caused by off-target effects. Compounds that can modulate the genome editing efficiency of the CRISPR/Cas9 system, especially those reducing the off-target effects, are potentially useful pharmacological tools for improving the effectiveness and safety of genome editing. Here, we performed high-throughput screening in HEK 293FT cells to discover compounds that decrease or increase the genome editing efficiency of the CRISPR/Cas9 system from 9930 compounds. After two rounds of screening, we identified that CP-724714, a ErbB2 (HER2) tyrosine kinase inhibitor, decreased the CRISPR/Cas9 efficiency and reduced the off-target effects by suppressing the efficiency of CRISPR/Cas9, and was thus named a CRISPR decelerator (or inhibitor), while Clofarabine, a DNA synthesis inhibitor, increased the efficiency of CRISPR/Cas9, and was named a CRISPR accelerator. We further identified four compounds (Tranilast, Cerulenin, Rosolic acid and Resveratrol) that affected the efficiency of single-strand annealing (SSA) repair. Among them, Tranilast, Cerulenin and Rosolic acid are potential SSA decelerators, while Resveratrol is a potential SSA accelerator. These identified compounds may be useful in optimizing mammalian genetic manipulation techniques.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2025) studied this question. High-throughput screening of 9930 compounds was evaluated on Genome editing efficiency of the CRISPR/Cas9 system. High-throughput screening identified CP-724714 as a CRISPR decelerator that reduces off-target effects, and Clofarabine as a CRISPR accelerator.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: